TherapeuticsMD, Inc. filed a definitive proxy statement on November 20, 2026, calling stockholders to a virtual annual meeting on December 30, 2026, to vote on director elections, executive compensation, and auditor ratification.

Key Highlights

  • Meeting date and format: The annual meeting is scheduled for December 30, 2026, at 8:00 a.m. Eastern Time, to be held exclusively as a virtual webcast.
  • Record date: Only stockholders of record as of the close of business on November 16, 2026, are entitled to notice of and to vote at the meeting.
  • Shares outstanding: As of the record date, 11,574,362 shares of common stock were issued and outstanding, with each share carrying one vote.
  • Proposal one: Stockholders will vote on the election of directors to serve until the next annual meeting or until their successors are duly elected and qualified.
  • Proposal two: A non-binding advisory say-on-pay vote covers named executive officer compensation for the fiscal year ended December 31, 2025.
  • Proposal three: Stockholders will consider ratifying the appointment of Carr, Riggs and Ingram, L.L.C. ("CRI") as the independent auditor for fiscal year ending December 31, 2026.
  • Signed by: The notice was issued by Marlan D. Walker, Chief Executive Officer, from Boca Raton, Florida.

TherapeuticsMD Annual Meeting Agenda and Voting Details

TherapeuticsMD, Inc. (NASDAQ:TXMD), a Nevada corporation headquartered at 951 Yamato Road, Suite 220, Boca Raton, Florida, issued this definitive proxy statement soliciting votes ahead of its annual stockholder meeting. The company describes itself as distributing proxy materials electronically to most stockholders in accordance with SEC rules, mailing a Notice of Internet Availability of Proxy Materials rather than a full paper copy of the proxy statement and 2025 Annual Report.

According to the filing, proxy solicitation materials were anticipated to be first distributed on or about November 20, 2026, to all stockholders entitled to vote. Stockholders holding shares registered directly with the company's transfer agent, Computershare Trust Company, N.A., as of the November 16, 2026 record date are considered stockholders of record and may vote virtually at the meeting or by proxy over the Internet, by mail, or by telephone, as described in the proxy card.

The filing states that even if a proxy is submitted before the meeting, a stockholder may still attend virtually, revoke the prior proxy, and cast a new vote. The board of directors, through Chief Executive Officer Marlan D. Walker, solicited the accompanying proxy for use at the December 30, 2026 meeting or any adjournment thereof. The three formal proposals before stockholders cover governance (director elections), compensation oversight (say-on-pay for fiscal year 2025), and audit oversight (CRI appointment for fiscal year 2026).

What Was Disclosed

TherapeuticsMD filed a definitive Schedule 14A proxy statement covering its 2026 annual stockholder meeting, disclosing 11,574,362 shares outstanding as of the November 16, 2026 record date and three formal proposals for stockholder vote on December 30, 2026.